Violite® – a cost effective equivalent to Microlite®3

  • Contains 20 mcg ethinylestradiol and 100mcg levonorgestrel, exactly the same active ingredients as Microlite®¹-²
  • Violite is GMS Reimbursed
  • Indicated for the prevention of pregnancy in women who elect to use an oral contraceptive¹
  • Violite TM has a Pearl Index of 0.44
  • Inhibits ovulation & causes changes in the cervical secretion¹
  • Reliable, reversible form of contraception if used correctly¹
  • Side effects may include depressed mood and depression.1

VIOLITE  is suitable for use in the following patient groups:⁵-⁶

  • Women who want autonomy and control over their menstrual cycle
  • Women aged up to 50 years with no other medical conditions
  • Women with a BMI of ≥34kg/m2 who do not smoke
  • Women ≥6 months postpartum if breast feeding
  • Women ≥21 days postpartum if not breast feeding
  • Women with dysmenorrhoea who have an irregular, heavy or prolonged bleeding pattern
  • Women with endometriosis


  1. Violite™ SmPC
  2. Microlite® SmPC available at
  3. MIMS Ireland (August 2017) “Contraception” MPI Media Ltd, Dublin.
  4. Faculty of Sexual and Reproductive Health Care (FSRH). First Prescription of Combined Oral Contraception. Clinical Effectiveness Unit July 2006 (Updated January 2007) London: FSRH, 2007.
  5. Faculty of Sexual and Reproductive Health Care (FSRH). UK Medical Eligibility Criteria for Contraceptive Use. UKMEC 2016. London: FSRH, 2016.
  6. WHO Guidelines. Medical Eligibility Criteria for contraceptive use 2015 update.

Web design by